Organigram Global (NASDAQ:OGI) Issues Earnings Results

Posted by Stanley Muller on May 14th, 2026

Organigram Global (NASDAQ:OGI – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.01) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.01), Zacks reports. The company had revenue of $42.99 million during the quarter, compared to analysts’ expectations of $50.56 million. Organigram Global had a negative net margin of 9.22% and a negative return on equity of 13.49%.

Here are the key takeaways from Organigram Global’s conference call:

OrganiGram reported a challenging Q2, with net revenue of CAD 59.8 million, down about 9% year over year, as execution issues in vapes and infused pre-rolls weighed on results.
Adjusted gross margin fell to 31% and adjusted EBITDA dropped to CAD 0.9 million, reflecting weaker mix, higher returns, and lower recreational revenue. Net loss also included a CAD 5.8 million impairment tied to the company’s U.S. hemp-derived products business.
Management said the main operational problems in pre-rolls and vapes have been identified and remediated, and they are already seeing improving quality and competitiveness. They expect recovery to continue in Q3 and Q4, alongside seasonal tailwinds.
The company emphasized strong underlying performance in other categories, including flower share gains, continued strength in edibles, beverages, and concentrates, and a record quarterly harvest of over 32,000 kilograms. OrganiGram also said its cultivation yields and genetics work are lowering costs and improving efficiency.
Management expects the Sanity Group acquisition to drive a meaningful step-up in the second half of fiscal 2026, supporting international growth, especially in Germany and other European markets. Reflecting this, OrganiGram raised guidance to net revenue above CAD 350 million, with adjusted EBITDA and adjusted gross margin above FY2025 levels and free cash flow near breakeven.

Organigram Global Price Performance

Organigram Global stock remained flat at $1.12 during midday trading on Thursday. 245,904 shares of the company traded hands, compared to its average volume of 755,592. Organigram Global has a 52-week low of $1.09 and a 52-week high of $2.24. The firm has a market cap of $156.96 million, a PE ratio of -8.58 and a beta of 1.50. The stock’s fifty day moving average price is $1.39 and its 200-day moving average price is $1.53.

Analyst Upgrades and Downgrades

OGI has been the subject of a number of research analyst reports. Wall Street Zen cut shares of Organigram Global from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Canaccord Genuity Group assumed coverage on shares of Organigram Global in a research report on Tuesday, January 27th. They set a “buy” rating for the company. Finally, ATB Cormark Capital Markets lowered shares of Organigram Global from a “strong-buy” rating to a “moderate buy” rating in a report on Wednesday, February 11th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Organigram Global currently has an average rating of “Hold”.

View Our Latest Research Report on Organigram Global

Institutional Investors Weigh In On Organigram Global

A number of institutional investors have recently made changes to their positions in the stock. Tidal Investments LLC increased its position in shares of Organigram Global by 4.9% during the second quarter. Tidal Investments LLC now owns 2,646,879 shares of the company’s stock valued at $3,573,000 after acquiring an additional 124,356 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Organigram Global by 43.2% during the fourth quarter. Renaissance Technologies LLC now owns 1,405,348 shares of the company’s stock valued at $2,361,000 after acquiring an additional 423,900 shares during the last quarter. Millennium Management LLC acquired a new stake in shares of Organigram Global during the fourth quarter valued at about $1,260,000. Goldman Sachs Group Inc. increased its position in shares of Organigram Global by 82.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 466,585 shares of the company’s stock valued at $784,000 after acquiring an additional 210,391 shares during the last quarter. Finally, Two Sigma Investments LP acquired a new stake in shares of Organigram Global during the third quarter valued at about $907,000. 34.63% of the stock is currently owned by institutional investors and hedge funds.

About Organigram Global

(Get Free Report)

Organigram Global Inc (NASDAQ: OGI) is a licensed producer of cannabis and hemp products headquartered in Moncton, New Brunswick, Canada. Founded in 2013, the company operates a state-of-the-art cultivation and manufacturing facility spanning more than one million square feet. Organigram holds licenses from Health Canada to produce and sell both medical and adult-use cannabis, and it pursues Good Manufacturing Practice (GMP) certification to support international exports.

The company’s product portfolio encompasses dried flower, pre-rolled joints, cannabis oils, capsules and soft gels, as well as vapourizer cartridges and extracts.